In 1982 the World Health Organization introduced a multidrug therapy (MDT) consisting of dapsone, rifampicin, and clofazimine for the worldwide control of leprosy,1 resulting in a dramatic reduction in the number of patients with leprosy over the past decade. More recently, several fluoroquinolone drugs, such as ofloxacin, sparfloxacin,2 and pefloxacin, have been introduced as new medicines against leprosy.
Report of a Case.
A 29-year-old Japanese-Paraguayan man presented with relapsed leprosy. About 14 years prior to our examination, he had been treated with antileprosy drugs for 1 year. Following a long quiescent period, he complained of severe pain and marked edema in the feet lasting 3 months, and several erythematous plaques on his trunk were observed. No sensory impairment of the skin lesions was noted, although both thickening and tenderness of nerve trunks were observed at the extremities. A skin biopsy specimen revealed patchy granulomatous lesions consisting of epithelial
Sugita Y, Suga C, Ishii N, Nakajima H. A Case of Relapsed Leprosy Successfully Treated With Sparfloxacin. Arch Dermatol. 1996;132(11):1397-1398. doi:10.1001/archderm.1996.03890350141036